NZ752587B2 - Lsd1 inhibitors and medical uses thereof - Google Patents
Lsd1 inhibitors and medical uses thereofInfo
- Publication number
- NZ752587B2 NZ752587B2 NZ752587A NZ75258717A NZ752587B2 NZ 752587 B2 NZ752587 B2 NZ 752587B2 NZ 752587 A NZ752587 A NZ 752587A NZ 75258717 A NZ75258717 A NZ 75258717A NZ 752587 B2 NZ752587 B2 NZ 752587B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- medical uses
- lsd1 inhibitors
- lsd1
- disorders
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Abstract
Provided are novel compounds of Formula (I or Ia'): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or la'), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
Claims (1)
1. Claims P
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413162P | 2016-10-26 | 2016-10-26 | |
| US201662413166P | 2016-10-26 | 2016-10-26 | |
| PCT/US2017/058405 WO2018081343A1 (en) | 2016-10-26 | 2017-10-26 | Lsd1 inhibitors and medical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ752587A NZ752587A (en) | 2025-09-26 |
| NZ752587B2 true NZ752587B2 (en) | 2026-01-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| EP4609866A3 (en) | Oxysterols and methods of use thereof | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| WO2017210545A8 (en) | Potassium channel modulators | |
| WO2019035914A8 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| WO2016109217A3 (en) | Btk inhibitors | |
| MX2020010690A (en) | Oxysterols and methods of use thereof. | |
| MX2017012393A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use. | |
| WO2016106331A8 (en) | Mutant idh1 inhibitors useful for treating cancer | |
| EA201792116A1 (en) | JANUS KINASE INHIBITOR | |
| WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| GEAP201814349A (en) | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | |
| MX2020001531A (en) | NEW HETOROCYCLIC COMPOUNDS AS INHIBITORS OF CDK8/19. | |
| WO2018201167A3 (en) | Propionic acid derivatives and methods of use thereof | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2021002878A (en) | Cd73 inhibitors and pharmaceutical uses thereof. |